Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Schlumberger NV — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Schlumberger NV trades at $53.7 (market cap $79.67B). The key difference: Schlumberger NV is far larger — about 15.7× ACADIA Pharmaceuticals Inc.'s market cap, and Schlumberger NV pays a 2.2% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SLB | |
|---|---|---|
Market Cap | $5.07B | $79.67B |
Sector | Health | Energy |
52-Week High | $29.41 | $58.01 |
52-Week Low | $20.06 | $31.72 |
Enterprise Value | $4.19B | $88.40B |
Dividend Yield | — | 2.2% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
